sur MEDINCELL (EPA:MEDCL)
Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes
Medincell, located in Montpellier, France, has upgraded its revenue forecast for its U.S.-marketed drug UZEDY®, a subcutaneous risperidone treatment for schizophrenia. Initially projected at around $160M, revenue expectations for 2025 have now been raised to $190-$200M. Teva Pharmaceuticals, Medincell’s partner, reported Q2 2025 sales of $54M, marking a 2.2-fold increase from Q2 2024, with H1 2025 sales at $93M, a 2.3-fold rise compared to H1 2024.
The Olanzapine Long-Acting Injectable (LAI), another Medincell prospect, completed its Phase 3 trial with positive efficacy results, free of PDSS, a significant complication. An NDA for this treatment is slated for Q4 2025, aiming to enhance schizophrenia management with improved safety and accessibility.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MEDINCELL